23% drop in Heart Attack & Stroke Risks in Diabetic Patients!
United States: The global number of chronic kidney disease patients stands at 840 million, according to researchers, since this condition causes permanent kidney harm, resulting in reduced organ function.
Diabetes affects approximately 828 million individuals internationally since their bodies do not produce or process insulin effectively.
The majority of diabetes patients, or 95 percent, suffer from type 2 diabetes, according to expert estimates.
More about the news
The two distinct chronic conditions create a relationship because type 2 diabetes affects one in every three adults who develops permanent kidney conditions.
People who have type 2 diabetes or chronic kidney disease develop elevated risks of experiencing patients Heart attacks and Stroke as cardiovascular complications.
A recent paper in The Lancet Diabetes & Endocrinology demonstrates that sotagliflozin, which functions as type 2 diabetes and kidney disease therapy for heart disease patients, can minimize stroke and heart attack incidences, Medical News Today reported.
Research findings
The research evaluated individuals suffering from type 2 diabetes and chronic kidney disease together with existing heart disease risks. The research subjects either used a placebo or took the medication sotagliflozin.
According to Deepak L. Bhatt, MD, MPH, MBA, director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai, and lead author of this study, “The SCORED trial examined patients with diabetes, kidney disease, and additional cardiovascular risks, because of the known high rate of cardiac problems these people face,” Medical News Today reported.
“We saw a significant benefit in terms of fewer heart failure and adverse kidney events. We wanted to see if heart attack and stroke risks might also be reduced,” he added.
Furthermore, “(Sotagliflozin) is a drug that blocks a receptor in the kidneys, called SGLT2 (sodium-glucose cotransporter 2), leading to glucose elimination in the urine, among many additional effects,” Bhatt noted.
“Other popular medications such as empagliflozin and dapagliflozin also block this receptor,” he continued.
Bhatt and his team examined the data of approximately 10,600 participants from the SCORED trial who got sotagliflozin or placebo treatment between 2017 and 2020, followed for nearly 16 months.
Scientists conducting the study discovered that people given sotagliflozin in the study reduced their chances of heart attack and stroke alongside cardiovascular death risks by 23 percent when compared to placebo recipients.
“The benefit occurred within just three months of starting the drug, which is … quite remarkable to see such an early effect in a stable, outpatient population,” Bhatt noted.
“Examined separately, there was a 32% reduction in heart attack and a 34% reduction in stroke,” he continued.
“People with diabetes and kidney disease are at very high risk of cardiovascular complications, such as heart attack and stroke,” he added. “We need new therapies to help reduce these risks.”
